Drug company Danco Laboratories on Friday asked the Greatest Court to review the case challenging the legality of the abortion pill mifepristone.

Danco’s request comes in response to a determining by the U.S. Court of Appeals for the Fifth Circuit that would impose major restrictions on how the medication is used and distributed to patients.

Danco, which orders the abortion pill, wants the Supreme Court to reverse the lower court ruling. The drug company said the encase is of “indisputable importance” to women’s health as well as the pharmaceutical industry.

“For the women and teenage girls, health care providers, and States that depend on FDA’s actions to guard safe and effective reproductive health care is available, this case matters tremendously,” Danco’s attorneys wrote in their documentation.

“And for the pharmaceutical and biotechnology industry, permitting judicial second-guessing of FDA’s scientific evaluations of data will have a wildly destabilizing meaning,” the attorneys wrote.

Danco’s request for the Supreme Court to take up the case comes nearly 15 months after the court’s cautious majority overturned Roe v. Wade, the landmark 1973 decision that protected abortion as a constitutional right. More than a dozen conditions have banned abortion in the wake of that ruling.

The Supreme Court’s new term starts next month. Four justices father to agree to take up the abortion pill case. The U.S. Department of Justice is also expected to ask the high court to review the happening.

Download Danco Laboratories’ filing here.

The appeals court ruling is on hold until the Supreme Court be bound for b assaults a decision about the case. The high court, in April, pressed pause on lower court decisions as litigation almost the pill proceeds in response to a request from the Biden administration.

A three-judge panel at the Fifth Circuit ruled that rulings the U.S. Food and Drug Administration took in recent years to make mifepristone more accessible to women failed to oration safety concerns.

Should the Supreme Court take the case and uphold the appeals court decision, mifepristone choose remain on the market in the U.S., but patients will face more barriers to accessing the medication.

If the high court declines to acquire the case, the appeals court restrictions will go into effect.

Mifepristone, used in combination with another sedate called misoprostol, is the most common method to terminate a pregnancy in the U.S.

The appeals court order would end mail delivery of mifepristone and prescriptions via telemedicine appointments. Women discretion have to see a doctor in person to get a prescription and go to three follow-up visits as they take the course of medication.

The ruling also abridges the time when women can take mifepristone to seven weeks into their pregnancy, down from 10 weeks currently.

The lawsuit against mifepristone began last November when a group of physicians who oppose abortion called the Alliance for Hippocratic Drug sued to overturn the FDA’s original approval of the pill, which dates back more than 20 years.

U.S. Expert Matthew Kacsmaryk of the U.S. District Court for the Northern District of Texas issued a sweeping order in April that dangled the FDA approval of mifepristone.

The appeals court dialed back Kacsmaryk’s order and kept the original FDA approval in place as fountain-head as the agency’s authorization of a generic form of the pill.